Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal Antibodies
Minimal residual disease (MRD) evaluation is a recognized endpoint in clinical trials. Both next-generation flow and sequencing could be used as complementary techniques to detect myeloma cells after therapy to measure the depth of response and novel drug efficacy. Anti-CD38 monoclonal antibodies co...
Na minha lista:
| Principais autores: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI AG
2025-01-01
|
| Serier: | Pharmaceuticals |
| Fag: | |
| Online adgang: | https://www.mdpi.com/1424-8247/18/2/159 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
